GNMA 1: Improving access to orphan medicines

IImproving access to orphan medicines – policy proposals to accelerate access.
As we approach the first consultation of NICE’s methods for health technology evaluation, this paper sets out details of some of the challenges that orphan medicines encounter via NICE’s single technology appraisal (STA) process and possible solutions.

This content is restricted to members. To view this content please register or login below to view this content.

Sign-Up For Free

Sign-up to receive up-to-date information and advice on tax developments within your industry.

Sign-up for free